"Debt Securities with irBBB rating have an adequate level of certainty to honor its financial obligations.

However, this certainty is more likely to diminish in the

"Debt securities with irA rating has a high level of

certainty to honor its financial obligations, but it can be

affected by adverse changes in business and

economic conditions, relative to debt securities with a

The positive sign (+) indicates that the rating given is

future than with the higher rating categories"

closer to the rating scale above it.

PT Pyridam Farma Tbk

higher rating"

Company rating _{ir}BBB+/Stable

Rated Issues

Obligasi Pyridam Farma I Tahun irA+ 2020 amounting to IDR 300 Bn Obligasi Berkelanjutan I Pyridam

Farma Tahap I Tahun 2022

amounting to IDR 1.2 Tn irBBB+

Rating Period

October 28, 2022 - November 1, 2023

Rating History

November, 2021 irBBB+/Stable October, 2021 _{ir}BBB+/Stable October, 2020 irBBB/Stable

Kredit Rating Indonesia affirms 'irA+' rating to Obligasi Pyridam Farma I Tahun 2020 totaling IDR 300 Bn and 'irBBB+' rating to Obligasi Berkelanjutan I Pyridam Farma Tahap I Tahun 2022 amounting to IDR 1.2 Tn

Kredit Rating Indonesia (KRI) affirms a Company Rating of '#BBB+' for PT Pyridam Farma Tbk (PYFA or the Company) with a 'Stable' outlook, and 'i/BBB+' rating to Obligasi Berkelaniutan I Pyridam Farma Tahap I Tahun 2022 amounting to IDR 1.2 trillion. At the same time, KRI also affirms 'iA+' rating to PYFA's Obligasi Pyridam Farma I Tahun 2020 amounting to IDR 300 billion as 50% of its total outstanding debt and interest amounting to IDR 225 billion is guaranteed by PT Asuransi Sinar Mas. The ratings were still driven by the Company's significant business improvement, while at the same time the ratings are still constrained by its weak financial profile.

PYFA just recently acquired another pharmaceutical company which is expected to increase the type of products owned as well as the target segments. This acquisition is expected to instantly affect the Company's revenue since the acquired company has already operated. However, the Company's ratings are still constrained by its aggressive capital structure with debt-to-equity ratio of 6.9x as of June 30, 2022, the most aggressive to its rated peer. PYFA's capacity to cover the interest expenses was also alarming as shown with the EBITDA-to-interest expense ratio of 0.5x and 0.6x as per December 31, 2021, and June 30, 2022.

PYFA's shareholder composition as of June 30, 2022 were Rejuve Global Investment Pte. Ltd., (40.48%), PT Aldiracita Sekuritas Indonesia (13.73%), PT Mirae Asset Sekuritas Indonesia (8.27%), DBS Bank Ltd SG-PB Clients (7.48%), PT Global Investment Institusi (5.50%), and the public (4.54%).

PYFA Financial Results Highlights (Consolidated)

As of/For the year ended	June 2022 (Unaudited)	Dec 2021 (Audited)	Dec 2020 (Audited)	Dec 2019 (Audited)
Total Assets (IDR, Bn)	1,179.3	761.4	228.3	190.6
Total Adjusted Debt (IDR, Bn)	912.4	448.8	35.5	19.4
Total Adjusted Equity (IDR, Bn)	131.3	122.3	157.4	124.6
Total Sales (IDR, Bn)	307.1	630.5	277.4	247.1
EBIT (IDR, Bn)	22.1	24.6	29.6	10.9
Net Income After MI (IDR, Bn)	9.3	5.8	22.1	9.3
EBIT Margin (%)	7.2	3.9	10.7	4.4
Return on Permanent Capital (%)	5.5	6.4	17.6	7.6
Adj. Debt/Adj. Equity (x)	7.0	3.4	0.2	0.2
EBITDA/Adj. Debt (x)	0.1	0.1	0.8	0.6
EBITDA/IFCCI (x)	0.6	0.6	11.5	3.9
FFO/Total Adjusted Debt (%)	2.0	1.2	84.1	86.4
USD Exchange Rate (IDR/USD)	14,848	14,269	14,105	14,481

: Achmad Kurniawan Sudjatmiko (Achmad.sudjatmiko@kreditratingindonesia.com) Analysts

Furqon Abrory Samara (Furqon.samara@kreditratingindonesia.com)

October 28, 2022

DISCLAIMER
PT Kredit Rating Indonesia (KRI) does not represent or warrant or guarantee the accuracy, completeness, timeliness or availability of the contents of this report or publication. KRI does not perform an audit and does not undertake due diligence or independent verification of any information used as the basis of and presented in this report or publication. Although the information upon which KRI rating report are based, and any other contents provide in this rating report is obtained by KRI from sources which KRI believers to be reliability of the contents of the information upon which KRI rating report are based, and any other contents provide in this rating report is obtained by KRI from sources which KRI believers to be reliability of the result of its use or lack of its use in any investment or other kind of financial decision making on which this report or publication is based. The issuance of a solicited or unsolicited rating report does not supply financial, legal, tax or investment consultancy. The rating report is not an oppinion as to the value of securities, herefore KRI is not responsible for any credit, loan or investment decision, damages or other losses resulting from the reliance upon or use of this report.

In one event shall KRI be held liable for any direct, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses including to tost profits and opportunity costs in connection with any use of the contents of this rating report or publication.

Credit analyses, including ratings, and statements in this report or publication are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities or to make any investment decision. Therefore, this report may not reflect any event or circumstances which occur after the date of this report.

KRI disc assumes no obligation to update the content following publication in any form. KRI does not act as flucia